Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
HelloRide Partners with EngageLab to Achieve Global User Operations in Shared Mobility
-
Dimensional Fund Advisors Ltd. : Form 8.3 - ME GROUP INTERNATIONAL PLC - Ordinary Shares
-
Canadian Home Sales Mark Four-Year High for the Month of September
-
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
-
CREA Updates Resale Housing Market Forecasts for 2025 and 2026
-
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
-
ENT and Allergy Associates, LLP Welcomes Ethan Moritz, MD to Its Offices in Woodbury and Voorhees, NJ
-
Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial
-
Form 8.5 (EPT/RI) - NCC Group plc
-
Form 8.5 (EPT/RI) - PRS REIT Plc
-
Form 8.5 (EPT/RI) - Treatt plc
-
Form 8.5 (EPT/RI) - Dowlais Group plc
-
Form 8.5 (EPT/RI) Greencore Group Plc
-
Correction: Form 8.3 - Frenkel Topping Group plc - Octopus Investments
-
CoinEx Charity Expands Its “Bridge to Hope” Mission with Starlink Deployment at the Philippines’ PDEA Academy
-
Form 8.3 - Unite Group plc
-
Humanoid Global Reports Progress on Cartwheel Robotics’ Flagship Humanoid Yogi
-
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
-
Commodity trade faces geopolitical turbulence, Willis reports
-
Share Buyback Transaction Details October 9 – October 15, 2025
-
Cointelegraph Research releases comprehensive HTX ventures report on market trends and digital asset outlook
-
Ekspress Grupp’s subsidiary Delfi Latvia facing contractual dispute regarding advertising sales
-
Conference on Zhu Xi's doctrine and global civilizations dialogue kicks off
-
Conference on Zhu Xi's doctrine and global civilizations dialogue kicks off
-
Facephi Unveils its Fraud Intelligence Report 2025: “Identity at Risk”
-
Facephi Unveils its Fraud Intelligence Report 2025: “Identity at Risk”
-
Bitwise accelerates staking momentum with Celestia ETP launch on Euronext Paris
-
TVM Capital Life Science Portfolio Company Smart Reporting to Acquire Fluency for Imaging - Uniting to Create Jacobian™ and Accelerate AI-Powered Reporting
-
Municipality Finance issues a USD 25 million tap under its MTN programme
-
Nasdaq Embeds Innovative AI Capabilities Within its Surveillance Platform
-
Securonix Named a Leader for Sixth Consecutive Time in the 2025 Gartner® Magic Quadrant™ for Security Information and Event Management
-
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
-
Release by Scatec secures additional lease agreements in Africa
-
Quadient Wins IDC 2025 SaaS Award for Customer Satisfaction in Accounts Receivable
-
Jakub Kubrak Launches Kubrak Wealth Advisors to Simplify Complex Wealth Management
-
Legacy Financial Launches ‘Closers Den’ Training Program, Led by Morad Ahmed
-
Regarding a new draft resolution for the item on the agenda of the General Meeting of Shareholders of AB “Ignitis grupė” to be held on 24 October 2025
-
-
Aspo has set science-based emission reduction targets – now approved by SBTi
-
Transaction in Own Shares
-
AS Tallink Grupp Investor Webinar introducing the results of the Q3 of 2025
-
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
-
Cornish Metals Files Technical Report for the South Crofty Tin Project Updated PEA on Sedar+
-
Pulsar Helium Inc. Announces Filing of Preliminary Short Form Base Shelf
-
NBPE - Transaction in Own Shares
-
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
-
OSB GROUP PLC - Transaction in Own Shares
-
Mahidol University, ZERO13 and Unique Transformation Join Forces to Drive Thailand’s Carbon Credit Ecosystem for Global Sustainability
-
Zero Cap Funding Publishes Free 2025 Report to Help Entrepreneurs Achieve Business Success
-
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
